Pharma’s Transformation towards Next-Generation Therapeutics

How to overcome novel challenges by reshaping operating models
Dr. Roman Hipp | Dr. Till Giese | Joey Wilson | Marcel Kuhn | Axel Pohnke
Jan 2024 | Strategy Paper | Anglais

Pharma’s Transformation towards Next-Generation Therapeutics

How to overcome novel challenges by reshaping operating models

Innovation plays a pivotal role in most industries. In the pharmaceutical industry, however, it has the potential to both save and enhance millions of lives. As the sector undergoes continuous trans­formation, it is possible to categorize the most groundbreaking innovations into distinct waves. The preceding wave was predominantly centered around biologics, such as antibodies, while the current wave is bringing forward new therapeutic mo­dalities called “next-generation therapeutics” or NGTs. “We are entering a new frontier in medical innovation […]” said then-FDA commissioner Scott Gottlieb in 2017, when Kymriah from Novartis became the first officially approved therapy with genetical­ly modified cells (CAR T-cell therapy) in the US. These new entities are achieving commercial ma­turity and reaching the market at an accelerated pace.

This strategy paper aims to provide information on the latest developments around next-generation therapeutics by offering fresh perspectives on their market and commercial dynamics as well as their scientific specialties. The paper places an emphasis on the NGT value chain, starting from the research and development that are involved through to the moment they hit the market and are rolled out. Additionally, Porsche Consulting has identified the seven most essential strategic imperatives for producing this new and innovative class of drugs.


types of next-generation therapies investigated: cell therapies, gene therapies, and nucleic acid therapies.


out of the 20 top pharmaceutical companies identified as having next-generation therapeutics in their pipelines, with US companies taking the lead in the market.


imperatives should be followed to adjust operating models in order to meet the specific demands of NGTs and succeed in the future.

Management Summary
  • NGTs are a new field for Pharma companies. Top players are positioning themselves to leverage the huge opportunities.
  • Building up expertise and gaining a competitive advantage in selected fields is key.
  • Significant investments are necessary, which must also provide a significant ROI.
  • The huge opportunities and risk of missing this innovative trend show the importance of entering this field.
  • The complexity involved requires an extremely strategic and elaborated approach.
  • If companies follow the seven imperatives described, they will have the chance to become real NGT champions.

Lisez maintenant l'intégralité du document stratégique

Nous contacter

Des conseils pertinents et à fort impact

Vous désirez échanger avec nos experts? Prenez contact avec nous.

Dr. Roman Hipp
Industry Lead Life Sciences



La transformation globale du secteur de la santé

Retour d'expérience des CEOs dans l'industrie pharmaceutique et la medtech

Greenshoring: Location Decisions in Reverse

How sustainability impacts reshoring in the automotive industry

B2B Platform Play

Revolutionizing the rules of B2B industries with platform business models